The Japanese Clinical Practice Guideline for Diabetes 2024 by the Japanese Diabetes Society recommends finerenone alongside ACEis or ARBs, SGLT-2is, and a GLP-1 RA for cardio- and renoprotective treatment to reduce the progression of nephropathy for people with DKD [44]. This evidence concerns the gene GLP1R and kidney disorder.